Guo S, Li L, Yin H. Cholesterol Homeostasis and Liver X Receptor (LXR) in Atherosclerosis. Cardiovasc Hematol Disord Drug Targets. 2018;18(1):27–33.

Article  CAS  PubMed  Google Scholar 

Chistiakov DA, Melnichenko AA, Myasoedova VA, Grechko AV, Orekhov AN. Mechanisms of foam cell formation in atherosclerosis. J Mol Med (Berl). 2017;95(11):1153–65.

Article  CAS  PubMed  Google Scholar 

Libby P. The changing landscape of atherosclerosis. Nature. 2021;592(7855):524–33.

Article  CAS  PubMed  Google Scholar 

Francque S, Szabo G, Abdelmalek MF, Byrne CD, Cusi K, Dufour JF, Roden M, Sacks F, Tacke F. Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors. Nat Rev Gastroenterol Hepatol. 2021;18(1):24–39.

Article  PubMed  Google Scholar 

Tanaka N, Aoyama T, Kimura S, Gonzalez FJ. Targeting nuclear receptors for the treatment of fatty liver disease. Pharmacol Ther. 2017;179:142–57.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Han X, Cui ZY, Song J, Piao HQ, Lian LH, Hou LS, Wang G, Zheng S, Dong XX, Nan JX, et al. Acanthoic acid modulates lipogenesis in nonalcoholic fatty liver disease via FXR/LXRs-dependent manner. Chem Biol Interact. 2019;311:108794.

Article  CAS  PubMed  Google Scholar 

Stols-Gonçalves D, Hovingh GK, Nieuwdorp M, Holleboom AG. NAFLD and Atherosclerosis: Two Sides of the Same Dysmetabolic Coin? Trends Endocrinol Metab. 2019;30(12):891–902.

Article  PubMed  Google Scholar 

Rohatgi A. Reverse cholesterol transport and atherosclerosis. Arterioscler Thromb Vasc Biol. 2019;39(1):2–4.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Becares N, Gage MC, Pineda-Torra I. Posttranslational modifications of lipid-activated nuclear receptors: focus on metabolism. Endocrinology. 2017;158(2):213–25.

Article  CAS  PubMed  Google Scholar 

Dixon ED, Nardo AD, Claudel T, Trauner M. The role of lipid sensing nuclear receptors (PPARs and LXR) and metabolic lipases in obesity, diabetes and NAFLD. Genes (Basel). 2021;12(5):645.

Article  CAS  PubMed  Google Scholar 

Parlati L, Regnier M, Guillou H, Postic C. New targets for NAFLD. JHEP Rep. 2021;3(6):100346.

Article  PubMed  PubMed Central  Google Scholar 

Rasheed A, Cummins CL. Beyond the foam cell: the role of LXRs in preventing atherogenesis. Int J Mol Sci. 2018;19(8):2307.

Article  PubMed  PubMed Central  Google Scholar 

Glaria E, Letelier NA, Valledor AF. Integrating the roles of liver X receptors in inflammation and infection: mechanisms and outcomes. Curr Opin Pharmacol. 2020;53:55–65.

Article  CAS  PubMed  Google Scholar 

Ni M, Zhang B, Zhao J, Feng Q, Peng J, Hu Y, Zhao Y. Biological mechanisms and related natural modulators of liver X receptor in nonalcoholic fatty liver disease. Biomed Pharmacother. 2019;113:108778.

Article  CAS  PubMed  Google Scholar 

Gao S, Xue X, Yin J, Gao L, Li Z, Li L, Gao S, Wang S, Liang R, Xu Y, et al. Danlou tablet inhibits the inflammatory reaction of high-fat diet-induced atherosclerosis in ApoE knockout mice with myocardial ischemia via the NF-kappaB signaling pathway. J Ethnopharmacol. 2020;263:113158.

Article  CAS  PubMed  Google Scholar 

Hao D, Danbin W, Maojuan G, Chun S, Bin L, Lin Y, Yingxin S, Guanwei F, Yefei C, Qing G, et al. Ethanol extracts of Danlou tablet attenuate atherosclerosis via inhibiting inflammation and promoting lipid effluent. Pharmacol Res. 2019;146:104306.

Article  CAS  PubMed  Google Scholar 

Ding M, Ma W, Wang X, Chen S, Zou S, Wei J, Yang Y, Li J, Yang X, Wang H, et al. A network pharmacology integrated pharmacokinetics strategy for uncovering pharmacological mechanism of compounds absorbed into the blood of Dan-Lou tablet on coronary heart disease. J Ethnopharmacol. 2019;242:112055.

Article  CAS  PubMed  Google Scholar 

Gao LN, Zhou X, Zhang Y, Cui YL, Yu CQ, Gao S. The anti-inflammatory activities of ethanol extract from Dan-Lou prescription in vivo and in vitro. BMC Complement Altern Med. 2015;15:317.

Article  PubMed  PubMed Central  Google Scholar 

Ma C, Zhang W, Yang X, Liu Y, Liu L, Feng K, Zhang X, Yang S, Sun L, Yu M, et al. Functional interplay between liver X receptor and AMP-activated protein kinase alpha inhibits atherosclerosis in apolipoprotein E-deficient mice - a new anti-atherogenic strategy. Br J Pharmacol. 2018;175(9):1486–503.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang L, Jiang M, Shui Y, Chen Y, Wang Q, Hu W, Ma X, Li X, Liu X, Cao X, et al. DNA topoisomerase II inhibitors induce macrophage ABCA1 expression and cholesterol efflux-an LXR-dependent mechanism. Biochim Biophys Acta. 2013;1831(6):1134–45.

Article  CAS  PubMed  Google Scholar 

Korolenko TA, Johnston TP, Tuzikov FV, Tuzikova NA, Pupyshev AB, Spiridonov VK, Goncharova NV, Maiborodin IV, Zhukova NA. Early-stage atherosclerosis in poloxamer 407-induced hyperlipidemic mice: pathological features and changes in the lipid composition of serum lipoprotein fractions and subfractions. Lipids Health Dis. 2016;15:16.

Article  PubMed  PubMed Central  Google Scholar 

Sankaranarayanan S, Kellner-Weibel G, de la Llera-Moya M, Phillips MC, Asztalos BF, Bittman R, Rothblat GH. A sensitive assay for ABCA1-mediated cholesterol efflux using BODIPY-cholesterol. J Lipid Res. 2011;52(12):2332–40.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ge Z, Zhang M, Deng X, Zhu W, Li K, Li C. Persimmon tannin promoted macrophage reverse cholesterol transport through inhibiting ERK1/2 and activating PPARγ both in vitro and in vivo. Journal of Functional Foods. 2017;38:338–48.

Article  CAS  Google Scholar 

Rosenson RS, Brewer HB Jr, Davidson WS, Fayad ZA, Fuster V, Goldstein J, Hellerstein M, Jiang XC, Phillips MC, Rader DJ, et al. Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport. Circulation. 2012;125(15):1905–19.

Article  PubMed  PubMed Central  Google Scholar 

Sviridov D, Mukhamedova N, Miller YI. Lipid rafts as a therapeutic target. J Lipid Res. 2020;61(5):687–95.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hafiane A, Genest J. ATP binding cassette A1 (ABCA1) mediates microparticle formation during high-density lipoprotein (HDL) biogenesis. Atherosclerosis. 2017;257:90–9.

Article  CAS  PubMed  Google Scholar 

Phillips MC. Is ABCA1 a lipid transfer protein? J Lipid Res. 2018;59(5):749–63.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yu XH, Zhang DW, Zheng XL, Tang CK. Cholesterol transport system: An integrated cholesterol transport model involved in atherosclerosis. Prog Lipid Res. 2019;73:65–91.

Article  CAS  PubMed  Google Scholar 

Westerterp M, Fotakis P, Ouimet M, Bochem AE, Zhang H, Molusky MM, Wang W, Abramowicz S, la Bastide-van GS, Wang N, et al. Cholesterol Efflux Pathways Suppress Inflammasome Activation, NETosis, and Atherogenesis. Circulation. 2018;138(9):898–912.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Maguire EM, Pearce SWA, Xiao Q. Foam cell formation: A new target for fighting atherosclerosis and cardiovascular disease. Vascul Pharmacol. 2019;112:54–71.

Article  CAS  PubMed  Google Scholar 

Bonamassa B, Moschetta A. Atherosclerosis: lessons from LXR and the intestine. Trends Endocrinol Metab. 2013;24(3):120–8.

Article  CAS  PubMed  Google Scholar 

Nakagawa Y, Shimano H. CREBH regulates systemic glucose and lipid metabolism. Int J Mol Sci. 2018;19(5):1396.

Article  PubMed  PubMed Central  Google Scholar 

Fessler MB. The challenges and promise of targeting the Liver X Receptors for treatment of inflammatory disease. Pharmacol Ther. 2018;181:1–12.

Article  CAS  PubMed  Google Scholar 

Zhang Y, Breevoort SR, Angdisen J, Fu M, Schmidt DR, Holmstrom SR, Kliewer SA, Mangelsdorf DJ, Schulman IG. Liver LXRα expression is crucial for whole body cholesterol homeostasis and reverse cholesterol transport in mice. J Clin Investig. 2012;122(5):1688–99.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang B, Tontonoz P. Liver X receptors in lipid signalling and membrane homeostasis. Nat Rev Endocrinol. 2018;14(8):452–63.

Article